BioCentury
ARTICLE | Strategy

New CAR shopping

October 16, 2014 7:00 AM UTC

With two papers in the literature this week solidifying the efficacy of CD19-based chimeric antigen receptor T cells, the question now is how many other targets are amenable to the approach. Target selection is among the most challenging tasks in the chimeric antigen receptor space and was a hotly discussed topic at last year's SciBX Summit on Innovation in Drug Discovery and Development.1

This week, Kite Pharma Inc. announced the publication in Lancet of results from a Phase I trial of KTE-C19 to treat relapsed/refractory acute lymphoblastic leukemia (ALL).2 In the 20-patient study, 14 (70%) had a complete response. Of the responders, 12 had no evidence of minimal residual disease...